Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8TAT6

UPID:
NPL4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8TAT6; Q8N3J1; Q9H8V2; Q9H964; Q9NWR5; Q9P229

BACKGROUND:
The NPLOC4-UFD1-VCP complex, involving the Nuclear protein localization protein 4 homolog, is crucial for the cellular mechanism of exporting misfolded proteins from the ER, ensuring proper protein degradation. This complex also plays a significant role in mitosis by regulating spindle disassembly and is involved in the formation of the nuclear envelope. Furthermore, NPLOC4's role in inhibiting type I interferon production via RIGI ubiquitination and degradation underlines its importance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Nuclear protein localization protein 4 homolog offers a promising pathway for developing novel therapeutic approaches. Its critical role in managing protein homeostasis, cell division, and immune responses provides a strategic target for therapeutic intervention in related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.